BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 20435193)

  • 1. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
    Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES
    Am Heart J; 2010 May; 159(5):833-40. PubMed ID: 20435193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
    Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and ECG left ventricular hypertrophy.
    Muiesan ML; Salvetti M; Di Castelnuovo A; Paini A; Assanelli D; Costanzo S; Badilini F; Vaglio M; Donati MB; Agabiti Rosei E; de Gaetano G; Iacoviello L;
    J Hypertens; 2017 Jan; 35(1):162-169. PubMed ID: 27662187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study.
    Calderón A; Barrios V; Escobar C; Ferrer E; Barrios S; González-Pedel V; Montoro P; Navarro-Cid J
    Clin Exp Hypertens; 2010 May; 32(3):145-53. PubMed ID: 20504121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM; Hille DA; Kjeldsen SE; Devereux RB
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
    Okin PM; Gerdts E; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B; Devereux RB;
    Hypertension; 2008 Jul; 52(1):100-6. PubMed ID: 18504323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM; Jern S; Devereux RB; Kjeldsen SE; Dahlöf B;
    Hypertension; 2000 Jan; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM; Devereux RB; Jern S; Julius S; Kjeldsen SE; Dahlöf B
    Am J Hypertens; 2001 Aug; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
    Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.
    van Kleef MEAM; Visseren FLJ; Vernooij JWP; Nathoe HM; Cramer MM; Bemelmans RHH; van der Graaf Y; Spiering W;
    J Hypertens; 2018 Sep; 36(9):1865-1873. PubMed ID: 29878973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM; Boman K; Gohlke-Baerwolf C; Kesäniemi YA; Nienaber C; Ray S; Egstrup K; Rossebø AB; Devereux RB; Køber L; Willenheimer R; Wachtell K
    Circulation; 2012 Jan; 125(2):346-53. PubMed ID: 22147903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension.
    Verdecchia P; Schillaci G; Borgioni C; Ciucci A; Gattobigio R; Zampi I; Porcellati C
    J Am Coll Cardiol; 1998 Feb; 31(2):383-90. PubMed ID: 9462583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies.
    Zhang H; Hu L; Wei X
    J Clin Hypertens (Greenwich); 2020 Feb; 22(2):254-260. PubMed ID: 31955500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.